A61P 25/32
Alcohol-abuse
A61P25/32 (Alcohol-abuse) appears on 2,671 US grants and 4,210 published applications in this corpus.
Search patents in A61P- Granted patents
- 2,671
- Published applications
- 4,210
- Assignees
- 1,080
- Inventors
- 6,255
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1979 | 1 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 3 | 0 |
| 1993 | 2 | 0 |
| 1994 | 1 | 0 |
| 1995 | 3 | 0 |
| 1996 | 6 | 0 |
| 1997 | 7 | 0 |
| 1998 | 2 | 0 |
| 1999 | 17 | 0 |
| 2000 | 16 | 0 |
| 2001 | 30 | 12 |
| 2002 | 63 | 105 |
| 2003 | 77 | 168 |
| 2004 | 85 | 269 |
| 2005 | 65 | 217 |
| 2006 | 139 | 246 |
| 2007 | 118 | 258 |
| 2008 | 137 | 263 |
| 2009 | 146 | 318 |
| 2010 | 170 | 397 |
| 2011 | 200 | 281 |
| 2012 | 191 | 222 |
| 2013 | 190 | 169 |
| 2014 | 160 | 181 |
| 2015 | 149 | 171 |
| 2016 | 123 | 149 |
| 2017 | 129 | 146 |
| 2018 | 103 | 118 |
| 2019 | 82 | 103 |
| 2020 | 61 | 98 |
| 2021 | 53 | 59 |
| 2022 | 39 | 59 |
| 2023 | 22 | 65 |
| 2024 | 30 | 49 |
| 2025 | 34 | 57 |
| 2026 | 15 | 30 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Tetrahydroisoquinoline compound as potassium channel modulator and preparation and application thereof11 Aug 2026US 12,703,687 B2Shanghai Zhimeng Biopharma, Inc.
- Modified release formulation for (-)-(3AR,4S,7AR)-4-hydroxy-4-m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester16 Jun 2026US 12,653,807 B2Novartis AG
- Formulations of dihydromyricetin and a permeabilizer2 Jun 2026US 12,642,785 B2Cheers Health, Inc.
- Use of oxygenated cholesterol sulfates for treating at least one of insulin resistance, diabetes, and prediabetes2 Jun 2026US 12,642,805 B2Medicis Pharmaceutical Corporation
- Compound and composition for inducing neuroprotection28 Apr 2026US 12,611,387 B2Ecole Pratique Des Hautes Etudes
- Substituted 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles for treating brain disorders8 Oct 2026US 2026/0308154 A1The Regents of the University of California
- Ingestible formulations comprising methylliberine and one or more sugars and their use to treat the adverse effects of alcohol consumption1 Oct 2026US 2026/0294917 A1Lucid Psycheceuticals Inc.
- GLP-1R and GCGR Agonist in the Treatment of Alcohol Use Disorder (AUD) in Subjects with Obesity or Overweight Human Beings17 Sep 2026US 2026/0273022 A1Spitfire Pharma LLC
- GLP-1R and GCGR in the Treatment of Alcohol-Associated Liver Disorders in Subjects with Obesity or Overweight Human Beings17 Sep 2026US 2026/0273023 A1Spitfire Pharma LLC
- Biodegradable Implant Including Naltrexone27 Aug 2026US 2026/0248716 A1Biocorrx
Most cited
By later US patents
- Dual variable domain immunoglobulin and uses thereof391US 7,612,181 B2Abbott Laboratories · 2009
- Dual variable domain immunoglobulin and uses thereof187US 8,258,268 B2Abbott Laboratories · 2012
- Aerosol generating devices and methods for generating aerosols suitable for forming propellant-free aerosols146US 7,040,314 B2Philip Morris USA Inc. · 2006
- Controlled release pharmaceutical compositions based on one or more pharmaceutically acceptable salts of gamma hydroxy-butyric acid131US 5,594,030 ALaboratorio Farmaceutico C.T.S.R.L. · 1997
- Delivery of erectile dysfunction drugs through an inhalation route120US 6,803,031 B2Alexza Molecular Delivery Corporation · 2004